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Purpose: The aim of this study was to investigate whether pathologic changes in 
zonula occludens-1 (ZO-1) are induced by interleukin-13 (IL-13) in the experi-
mental minimal-change nephrotic syndrome (MCNS) model and to determine 
whether montelukast, a leukotriene receptor antagonist, has an effect on ZO-1 res-
toration in cultured human podocytes. Materials and Methods: Human podo-
cytes cultured on bovine serum albumin-coated plates were treated with different 
doses of IL-13 and montelukast and then examined for distribution using confocal 
microscopy and for ZO-1 protein levels using Western blotting. Results: ZO-1 
was internalized and shown to accumulate in the cytoplasm of human podocytes 
in an IL-13 dose-dependent manner. High doses (50 and 100 ng/mL) of IL-13 de-
creased the levels of ZO-1 protein at 12 and 24 h (both p<0.01; n=3), which were 
significantly reversed by a high dose (0.5 μM) montelukast treatment (p<0.01; 
n=3). Conclusion: Our results suggest that IL-13 alters the expression of ZO-1, 
and such alterations in the content and distribution of ZO-1 may be relevant in the 
pathogenesis of proteinuria in the MCNS model.
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INTRODUCTION
Although minimal-change nephrotic syndrome (MCNS) is the most common 
cause of nephrotic syndrome during childhood, the various proteins involved in 
the morphological and functional changes of cytoskeletal proteins in MCNS are 
still elusive.1 The hallmark of MCNS pathology is the foot process (FP) efface-
ment of podocytes. Physiologically, FPs remain wide open to serve as a passage 
for glomerular filtrate and are held together by tenuous slit diaphragms (SDs) that 
connect the filtration slits.2 Glomerular SDs, a major selective barrier for proteins, 
reside in the cell-to-cell contact sites between neighboring podocytes, which are 
thought to be modified adherens junctions that consist of an increasing number of 
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MATERIALS AND METHODS
Cell culture of human podocytes
Human conditionally immortalized podocytes (AB8/23), 
primarily cloned from human glomerular cultures, were 
characterized and generously provided by Dr. Moin A. Sal-
eem (University of Bristol, Bristol, UK). Human podocytes 
were maintained in RPMI 1640 (WelGENE Inc., Daegu, 
South Korea) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), Insulin-Transferrin-Selenium-Pyru-
vate Supplement (ITSP; WelGENE Inc.), and antibiotics. 
Fresh media was supplied once every 2 days. 
To stimulate human podocyte proliferation, cells were 
cultivated at 33°C (permissive conditions) in a culture medi-
um supplemented with human recombinant ITSP to induce 
expression of temperature-sensitive large T antigens. To in-
duce differentiation, podocytes were maintained at 37°C 
(non-permissive conditions) for at least 2 weeks, and for 
subcultures, 0.05% trypsin was used to detach cells from the 
culture dishes.18
IL-13 and montelukast treatment conditions
To imitate MCNS-like conditions, cells were incubated with 
various concentrations of IL-13 (Peprotech Inc., Rocky Hill, 
NJ, USA) during the indicated time periods (6, 12, and 24 
h). IL-13 was administered in 3, 5, 10, 30, 50, and 100 ng/
mL doses into 0.5% RPMI with montelukast (Sigma-Al-
drich Inc., St. Louis, MO, USA) at 37°C. 
Immunofluorescence staining
Human podocytes that were grown on type I collagen-coat-
ed glass cover slips were incubated at 37°C for 2 h and fixed 
in 4% paraformaldehyde for 20 min. The cells were then 
permeabilized in 0.1% tritonX-100 for 10 min, blocked with 
10% FBS for 30 min, washed three times for 5 min in phos-
phate buffered saline (PBS), and labeled with monoclonal 
rabbit anti-ZO-1 antibody (Invitrogen, Eugene, OR, USA). 
Phalloidin-FITC (Sigma-Aldrich Inc.) was utilized to stain 
F-actin. Primary antibody-bound specimens were incubated 
with 1:1000 (v/v) Alexa 594 for red conjugates and Alexa 
488 for green (Invitrogen), respective of secondary anti-
rabbit IgG, at room temperature for 40 min and at 37°C for 
20 min without CO2. Nuclei were stained with 4’-6-diamid-
ino-2-phenylindole (DAPI) (1:1000) for 20 min in PBS. 
Coverslips were mounted in aqueous mountant and viewed 
with a fluorescence microscope (Leica TCS SP2 AOBS, 
proteins, including nephrin, CD2-associated protein 
(CD2AP), Neph-1, -2, and -3, podocin, and zonula oc-
cludens-1 (ZO-1).3 
Recent studies have identified that increased interleu-
kin-13 (IL-13) expression can lead to podocyte injury and 
induce a minimal-change-like nephropathy.4-6 Notably, Lai, 
et al.7 reported that overexpression of IL-13 caused down-
regulation of nephrin, podocin, and dystroglycan‒all of 
which are important molecules in maintaining SD integri-
ty‒and a concurrent upregulation of B7-1 as well as MCNS 
in a rat experiment model. Although receptors for IL-13 
such as IL-13Rα1 and IL-13Rα2 have also been demon-
strated to exist in cultured podocytes,8 the precise role of 
IL-13 is still not clear in the pathogenesis of MCNS, and 
there has been no report on the effects of IL-13 on cultured 
human podocytes in vitro.
While ZO-1 was originally identified as a tight junction 
component, this molecule was also found to be localized at 
adherens junctions in podocytes.9-12 ZO-1 is a cytosolic 
scaffold that connects the cadherin-catenin complex and ac-
tin-based cytoskeletons.9 It is thought to play a key role in 
adherens junctions through its interaction with various ad-
herens-junction proteins and the formation of multimolecu-
lar complexes.10 Therefore, we hypothesized that IL-13 
may play an important role in the development of protein-
uria in MCNS by exerting a direct effect on ZO-1 in human 
podocytes.
Leukotrienes are proinflammatory arachidonic acid me-
tabolites produced by leukocytes, eosinophils, mast cells, 
and macrophages via 5-lipoxygenase.13,14 Leukotrienes are 
involved in inflammatory cell recruitment, bronchocon-
striction, vasodilatation, increased microvascular permea-
bility, exudation of macromolecules, and edema; these in-
teractions are well-described in the pathophysiology of 
asthma.14-16 Although not studied extensively yet in the 
field of nephrology, IL-13 is known to influence leukotri-
ene levels.17 By inhibiting the proinflammatory effects of 
leukotriene, leukotriene receptor antagonist (LTRA) mon-
telukast may be useful in the treatment of MCNS. IL-13-
1112C/T polymorphism and the haplotype of IL-13 polymor-
phisms are also associated with LTRA drug responsiveness 
and useful as a target for modulation of LTRA drug re-
sponsiveness.17 Therefore, the aim of our study was to in-
vestigate the effects of IL-13 on ZO-1 and to determine 
whether LTRA could be effective in stabilizing the ZO-1 
proteins in an experimental model of MCNS induced by 
IL-13.
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propriate under different conditions. Statistical significance 
was evaluated by the non-parametric Kruskal-Wallis analy-
sis or Student’s t-test. p values <0.05 were considered sig-
nificant.
RESULTS
 
ZO-1 Distribution on confocal microscopy
Podocytes were double-stained for ZO-1 and F-actin, and 
the cell nuclei were stained with DAPI. ZO-1 in human 
podocytes was highly expressed within the podocyte in the 
cytoplasmic aspect of the FP membrane, adjacent to the in-
sertion of the SD, and colocalized with β-catenin (Fig. 1A). 
Staining for ZO-1 was most intense in the cytoplasmic sur-
face of the podocyte FP. ZO-1 and F-actin did not overlap 
and were located at different sites in the confocal images. 
From low to high IL-13 concentrations, ZO-1 staining be-
came blurry, which indicated a relocalization of ZO-1 away 
from the peripheral cell membrane. In the human podo-
cytes under IL-13 conditions, ZO-1 was internalized into 
the cytoplasm from the peripheral cell membrane as IL-13 
concentrations increased (Fig. 1A). These distributional 
changes were also observed in F-actin, particularly at the 
higher IL-13 concentrations (Fig. 1A). Moreover, in high-
resolution microscopy, ZO-1 was distributed to the cell 
contact areas under physiologic conditions without IL-13 
yet was redistributed and accumulated into the cytoplasm 
around the nucleus during a 6-hour incubation period as IL-
Mannheim, Germany).
Western blotting
Confluent cell layers were incubated with additives for var-
ious time durations, and proteins were extracted using a 
protein extraction solution PRO-PREP (Intron Biotechnolo-
gy, Seongnam, Gyeonggi, South Korea) containing phenyl-
methylsulfonyl fluoride, ethylenediamine tetraacetic acid, 
pepstatin A, leupeptin, and aprotinin; protein concentrations 
were then determined as previously described.19 To perform 
Western blotting for ZO-1, 30 μg of boiled extracts were re-
solved on 10% SDS-PAGE gels and transferred to polyvinyl-
idene difluoride (PVDF) membranes (Millipore Corp., Med-
ford, MA, USA).
The membranes were then washed with methanol and 
blocked in 5% fat-free milk before incubation with mono-
clonal rabbit anti-ZO-1 (Invitrogen). Anti-β-tubulin antibody 
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) 
was used as a loading control. After incubation with horse-
radish peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology), protein bands were detected using 
the enhanced chemiluminescence (ECL) detection system 
(WEST-ZOL® plus; Amersham Biotech Ltd., Bucks, UK). 
Density values are expressed as percentages of the control. 
Data on densitometric analysis of the ZO-1/β-tubulin ratio 
are expressed as mean±standard deviation.
Statistical analysis
Results are described as mean±standard deviation, as ap-
Fig. 1. Distributional changes in ZO-1 by IL-13 in human podocytes. ZO-1 was distributed at the peripheral cell membrane and colocalized with β-catenin and 
actin filament at cell-to-cell contact junctions. High concentrations of IL-13 suppressed and disrupted the immunostaining and linearity of ZO-1 proteins, and 
accumulated ZO-1 proteins into the cytoplasm around nucleus (A), which improved by treatment with 0.5 μM montelukast (B). Magnification: 1000×; Scale 
bar=20 μm. ZO-1, zonula occludens-1; IL-13, interleukin-13.
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13 may induce a minimal-change-like nephropathy through 
a reduction in ZO-1 molecules, which can be reversed by a 
high dose of the LTRA montelukast.
DISCUSSION
The main goal of this study was to determine whether patho-
logical changes in ZO-1 protein levels could be induced by 
IL-13. We demonstrated a redistribution and reduction in 
ZO-1 proteins from human podocytes treated with IL-13. 
The exposure of ZO-1 molecules to IL-13 caused ZO-1 to 
move and accumulate internally toward the cytoplasmic ac-
tin filaments, suggesting that the observed redistribution 
and reduction in ZO-1 proteins could be involved in the 
pathogenesis of MCNS. These results are similar to our 
previous studies that found that ZO-1 proteins in podocytes 
were also affected by diabetic conditions, causing hyper-
permeability at early stages.20,21  
Recent studies have shown strong evidence that protein-
uria in MCNS is associated with cytokines and T cell dis-
orders that result in glomerular podocyte dysfunction,4,5,22 
as well as B7-1 (CD80) that is expressed on the surface of 
B cells. An increase in IL-13 production by CD3+, CD4+, 
and CD8+ T cells was shown to mediate steroid-sensitive 
nephrotic syndrome in relapse.4,5 Of note, Lai, et al.7 demon-
13 increased from 0 to 30 ng/mL (Fig. 1B). These results 
suggest that IL-13 may have a substantial impact on the re-
distribution and rearrangement of ZO-1 molecules and may 
also disrupt the cytoskeletal connections between F-actin 
and α-catenin-β-catenin complex in a concentration-depen-
dent manner (Fig. 1A). The internalized ZO-1 proteins were 
restored to the periphery by treatment with a high dose of 
0.5 μM montelukast (Fig. 1B).
ZO-1 protein assayed by Western blotting
A major ZO-1 protein band was found at 205 kDa, and ZO-1 
levels were compared with β-tubulin. In human podocytes, 
density values for ZO-1 protein tended to decrease with IL-
13 treatment in a dose-dependent manner at 12 and 24 h. 
The highest dose (100 ng/mL) of IL-13 significantly de-
creased the amount of ZO-1 protein by 37.5% at 12 h and 
by 39% at 24 h (both p<0.01; n=3) (Fig. 2). Similarly, a 
dose of 50 ng/mL IL-13 significantly decreased the amount 
of ZO-1 protein by 31.0% at 12 h and by 34.9% at 24 h 
(both p<0.01; n=3) (Fig. 2). A dose of 10 ng/mL of IL-13 
also decreased ZO-1 protein levels to a greater degree at 24 
h (35.1%; p<0.05) than at 12 h (Fig. 2). The ZO-1 protein 
levels that had been reduced by 30 ng/mL IL-13 were re-
stored by a high dose of 0.5 μM montelukast (p<0.01; n=3); 
however, the reduced levels were not affected by only 0.2 
μM of montelukast (Fig. 3). These results suggest that IL-
Fig. 2. Effects of IL-13 on ZO-1 protein levels in cultured human podocytes as assayed by Western blotting. ZO-1 levels significantly decreased at IL-13 con-
centrations of more than 50 ng/mL at 12 and 24 h incubations, compared with the control. Data on the densitometric analysis of the ZO-1/β-tubulin ratio are 
expressed as mean±SD. Control (100%): the value of (-). *p<0.05. †p<0.01. ZO-1, zonula occludens-1; IL-13, interleukin-13. 
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over the GBM, and reconstruction of the SD.3,23 Permselec-
tivity of the glomerular filtration barrier, which is composed 
of a charge-selective barrier and a size-selective barrier, 
also plays a key role in restricting passage of plasma pro-
teins across the GBM and SD.25,26
ZO is a member of the membrane-associated guanylate 
kinase homologue family of proteins characterized by their 
PSD-95/discs-large/Zonula occludens-1 (PDZ) domain; 
these proteins are critical regulators of tight and adherens 
junction assembly.27 ZO connects several types of SD pro-
teins through its PDZ domain to the actin cytoskeleton. Al-
though ZO-1 was originally identified as a tight junction 
component, ZO-1 migrates from its apical location down to 
the level of the slit membrane at the capillary loop stage of 
renal development, where it is observed in a punctuate pat-
tern along the filtration slits.28 There are three ZO proteins, 
ZO-1, -2, and -3, which are multi-domain polypeptides.10 
Of these three molecules, ZO-1 has been proposed to be a 
scaffolding protein between transmembrane and cytoplas-
mic proteins and possibly forms a link between actin and 
the cadherin-catenin complex.27 ZO-1 may also participate 
in signaling events through tyrosine phosphorylation29 and 
binds directly to α-catenin and actin located on the FPs at 
the insertions of the SD.28,30 ZO-1 forms a gasket that seals 
off the intercellular spaces and restricts the movement of 
proteins, water and solutes along the paracellular pathway 
at tight junctions, maintaining the polarized distribution of 
membrane proteins.27 However, the functions of ZO-1 be-
strated that IL-13-transfected rats developed a minimal-
change-like glomerulopathy, as characterized by significant 
worsening of albuminuria over time, generalized swelling, 
low serum albumin, and hypercholesterolemia. In IL-13- 
transfected rats, light microscopy showed an absence of 
significant glomerular changes; however, electron micros-
copy revealed up to 80% effacement of podocyte FPs, which 
progressed the nephrotic syndrome.7 Although the nephrot-
ic-range proteinuria was selective in IL-13-transfected rats, 
no relationship between serum IL-13 and urinary albumin 
excretion or serum albumin levels was observed.7 Thus, our 
study attempted to define the pathogenic relationship be-
tween IL-13 and ZO-1 protein in the development of podo-
cyte FP effacement with nephrotic-range proteinuria, espe-
cially in human podocytes.
The proteinuric conditions in MCNS are usually associat-
ed with ultrastructural changes in podocytes, with fusion, 
widening, retraction, and gradual simplification of the high-
ly specialized interdigitating FPs, which are also accompa-
nied by alterations in the permselectivity of the SD glomeru-
lar filtration barrier and the linking of adaptor proteins, 
including nephrin, podocin, CD2AP, catenins, and ZO-1.22-24 
Maintenance of podocyte FP structure is pivotal for accu-
rate functioning of the glomerular filtration barrier. The FP 
effacement results from the detachment of podocytes from 
the glomerular basement membrane (GBM), and FP retrac-
tion leads to disintegration of the cytoskeletal structure and 
linking adaptor proteins, abnormal movement of the FP 
Fig. 3. Effects of montelukast on ZO-1 protein levels in cultured human podocytes assayed by Western blotting. Montelukast (0.5 μM) significantly increased 
ZO-1 levels in human podocytes treated with IL-13. *p<0.05. †p<0.01. ZO-1, zonula occludens-1; IL-13, interleukin-13. 
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and restored the normal localization of ZO-1 at the SD in the 
spontaneously proteinuric Munich-Wistar-Froemter rats.38 
Additional future studies are necessary to elucidate the ex-
act mechanisms, efficacy, and proper dose of LTRA in the 
in vivo treatment of MCNS in the future.
In conclusion, our study may provide a base for under-
standing the ZO-1 molecule in human podocytes. High con-
centrations of IL-13 increased the disruption of glomerular 
filtration barrier in SD and FP effacement. ZO-1 proteins 
were redistributed and reduced in IL-13-treated human podo-
cytes, which was significantly restored after treatment with 
an LTRA montelukast. Therefore, our findings further 
strengthen the hypothesis that IL-13 may alter the expression 
of ZO-1 proteins, resulting in proteinuria, and also provide 
an explanation for the plausible connection of Th2 cyto-
kines, MCNS, and atopy.
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